Idiopathic CD4 lymphocytopenia

Idiopathic CD4 lymphocytopenia (ICL) is a rare immunodeficiency disorder characterized by persistently low levels of CD4+ T lymphocytes (fewer than 300 cells per microliter of blood, or less than 20% of total T lymphocytes) in the absence of HIV infection or any other known cause of immunodeficiency. First formally defined by the Centers for Disease Control and Prevention (CDC) in 1992, ICL is sometimes referred to as "HIV-negative AIDS" in lay terms, though this is a misnomer. The condition primarily affects the immune system, leaving patients vulnerable to a wide range of opportunistic infections that are typically seen in immunocompromised individuals. Clinical manifestations of ICL are highly variable. Many patients present with opportunistic infections, including cryptococcal meningitis, progressive multifocal leukoencephalopathy (PML), non-tuberculous mycobacterial infections, severe human papillomavirus (HPV)-related disease, and invasive fungal infections such as histoplasmosis or candidiasis. Some patients also develop autoimmune conditions or malignancies, particularly lymphomas and HPV-associated cancers. The condition affects both men and women, and while most cases are diagnosed in adulthood, it can occasionally present in younger individuals. Some patients may remain asymptomatic and are discovered incidentally through routine blood work. The underlying cause of ICL remains unknown in most cases, though recent research has identified rare genetic variants in genes involved in T-cell homeostasis (such as UNC119, MAGT1, and RAG1) in a subset of patients, suggesting possible genetic contributions. Treatment is primarily directed at managing and preventing opportunistic infections, as there is no established curative therapy. Some patients have been treated with interleukin-2 (IL-2), interferon-gamma, or interleukin-7 (IL-7) in clinical settings to attempt to boost CD4+ T-cell counts, with variable results. Long-term monitoring of CD4 counts and vigilance for infections and malignancies are essential components of ongoing care.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Idiopathic CD4 lymphocytopenia